A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid‐derived suppressor cells for Agaricus bisporus–induced prostate‐specific antigen responses

By  

CANCER, Vol. 121, Iss. 17, 2015-09 ,pp. : 2942-2950

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 1b, multicenter, single blinded, placebo‐controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4268-4276

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I Study of Prolonged-Infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Carcinoma of the Breast: Tolerability of an Optimal Dose Schedule

By  

Oncology, Vol. 77, Iss. 1, 2009-06 ,pp. : 63-70

Karger

Access to resources Recommend Favorite

A phase I trial assessing the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of single‐dose Auron Misheil therapy in healthy male subjects

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 38, Iss. 1, 2013-02 ,pp. : 3-11

John Wiley & Sons Inc

Access to resources Recommend Favorite